One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients.

被引：0
|
作者：
Torres, A
De Broe, ME
D'Haese, PC
Hutchison, A
Jones, C
机构：
[1] Univ Canaries Hosp, Dept Nephrol, Tenerife, Spain
[2] Univ Antwerp, Dept Nephrol, B-2020 Antwerp, Belgium
[3] Manchester Royal Infirm, Inst Nephrol & Transplantat, Manchester M13 9WL, Lancs, England
[4] Shire Pharmaceut Grp Plc, Basingstoke, Hants, England
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：764A / 764A
页数：1
相关论文
共 50 条
  • [1] The effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients
    Haese, PCD
    Hutchinson, A
    Freemont, TJ
    De Broe, ME
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : A17 - A17
  • [2] A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients
    D'Haese, PC
    Spasovski, GB
    Sikole, A
    Hutchison, A
    Freemont, TJ
    Sulkova, S
    Swanepoel, C
    Pejanovic, S
    Djukanovic, L
    Balducci, A
    Coen, G
    Sulowicz, W
    Ferreira, A
    Torres, A
    Curic, S
    Popovic, M
    Dimkovic, N
    De Broe, ME
    KIDNEY INTERNATIONAL, 2003, 63 : S73 - S78
  • [3] A RANDOMIZED, OPEN-LABEL, CROSSOVER DESIGN STUDY TO COMPARE THE SAFETY AND EFFICACY OF SEVELAMER CARBONATE VERSUS CALCIUM CARBONATE IN THE TREATMENT OF HYPERPHOSPHATAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
    Ibrahim, Fairol H.
    Fadhlina, Nor Z.
    Ng, Eng K.
    Thong, Kah M.
    Goh, Bak L.
    Sulaiman, Dalimi M.
    Fatimah, Diana A. N.
    Evi, Diana O.
    Siti, Suraya R.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 470 - 470
  • [4] A prospective randomized Open-Label study comparing the efficacy and safety of intraperitoneal iron versus intravenous iron in peritoneal dialysis patients.
    Bhandari, S
    Moniem, KA
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 857A - 858A
  • [5] Efficacy and safety of lanthanum carbonate in German patients on dialysis
    Dellanna, Frank
    Reichel, Helmut
    Seibt, Frank
    CLINICAL NEPHROLOGY, 2012, 78 (05) : 382 - 390
  • [6] Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenol®) during long-term therapy in hemodialysis patients.
    Hutchison, A
    Webster, I
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 764A - 764A
  • [7] Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients:: an open-label, randomized study
    Sadek, T
    Mazouz, H
    Bahloul, H
    Oprisiu, R
    El Esper, N
    El Esper, I
    Boitte, F
    Brazier, M
    Moriniere, P
    Fournier, A
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (03) : 582 - 589
  • [8] One-Year Open-Label Safety and Efficacy Study of Paliperidone Extended-Release Tablets in Patients With Schizophrenia
    Kramer, Michelle
    Simpson, George
    Maciulis, Valentinas
    Kushner, Stuart
    Liu, Yanning
    Lim, Pilar
    Hough, David
    Palumbo, Joseph
    Eerdekens, Marielle
    CNS SPECTRUMS, 2010, 15 (08) : 506 - 514
  • [9] Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial
    Takahara, Yuki
    Matsuda, Yoshimi
    Takahashi, Shunichi
    Shigematsu, Takashi
    CLINICAL NEPHROLOGY, 2014, 82 (03) : 181 - 190
  • [10] An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis
    Wasilewska, Anna
    Murray, Rose Ann
    Sundberg, Aimee
    Uddin, Sharif
    Achenbach, Heinrich
    Shavkin, Aleksey
    Szabo, Tamas
    Vergani, Andrea
    Umeh, Obi
    BMC NEPHROLOGY, 2022, 23 (01)
12345